Literature DB >> 24549686

[Drusen characteristics after internal limiting membrane peeling].

F Lehmann1, T Jenisch, H Helbig, M A Gamulescu.   

Abstract

BACKGROUND: There are some reports showing isolated cases of drusen regression after pars plana vitrectomy (ppV) with peeling of the internal limiting membrane (iLM). Drusen characteristics after iLM peeling was investigated in this study. PATIENTS AND METHODS: The data of 527 patients who had received iLM peeling between 2004 and 2012 were retrospectively collected and those patients with retinal drusen were selected for the study. Fundus photographs before and after vitrectomy due to a macular hole or epiretinal gliosis were compared and drusen arrangement in the peeling site was analyzed. The aim of the study was to show whether there was drusen regression 2-5 months after surgery.
RESULTS: Out of the 527 patients 11 showed central macular drusen, 4 with confluent large drusen (> 63 µm diameter) and 7 with small hard drusen (≤ 63 µm diameter). One patient showed drusen regression after iLM peeling without any changes in the other eye and all other patients showed no differences in the drusen findings (n = 6) or even some additional drusen (n = 4) without drusen alterations in the other eye.
CONCLUSION: The results of this study could not confirm some reports showing drusen regression after iLM peeling in the peeling site in general and there was only one single case of central drusen regression.

Entities:  

Mesh:

Year:  2015        PMID: 24549686     DOI: 10.1007/s00347-013-3007-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  12 in total

1.  Disappearance of soft drusen following macular hole surgery.

Authors:  F G Holz; S Staudt
Journal:  Retina       Date:  2001       Impact factor: 4.256

2.  Pars plana vitrectomy for regression of choroidal neovascularization with age-related macular degeneration.

Authors:  T Ikeda; H Sawa; K Koizumi; T Yasuhara; T Yamasaki
Journal:  Acta Ophthalmol Scand       Date:  2000-08

3.  Evolution of soft drusen in age-related macular degeneration.

Authors:  J P Sarks; S H Sarks; M C Killingsworth
Journal:  Eye (Lond)       Date:  1994       Impact factor: 3.775

4.  Evolution of geographic atrophy of the retinal pigment epithelium.

Authors:  J P Sarks; S H Sarks; M C Killingsworth
Journal:  Eye (Lond)       Date:  1988       Impact factor: 3.775

5.  Drusen and disciform macular detachment and degeneration.

Authors:  J D Gass
Journal:  Arch Ophthalmol       Date:  1973-09

6.  Interactions between sensory cells, glial cells and the retinal pigment epithelium and their response to photocoagulation.

Authors:  J Marshall
Journal:  Dev Ophthalmol       Date:  1981

7.  Retinal precursors and the development of geographic atrophy in age-related macular degeneration.

Authors:  Michael L Klein; Frederick L Ferris; Jane Armstrong; Thomas S Hwang; Emily Y Chew; Susan B Bressler; Suresh R Chandra
Journal:  Ophthalmology       Date:  2007-11-05       Impact factor: 12.079

8.  Choroidal neovascularization in the Choroidal Neovascularization Prevention Trial. The Choroidal Neovascularization Prevention Trial Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1998-08       Impact factor: 12.079

9.  Functional aspects of drusen regression in age-related macular degeneration.

Authors:  F B Sallo; E Rechtman; T Peto; D Stanescu-Segall; G Vogt; A C Bird; F W Fitzke
Journal:  Br J Ophthalmol       Date:  2009-06-16       Impact factor: 4.638

10.  Effects of argon (green) laser treatment of soft drusen in early age-related maculopathy: a 6 month prospective study.

Authors:  I C Frennesson; S E Nilsson
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

View more
  1 in total

1.  Disappearance of soft drusen and subsequent development of choroidal neovascularization following macular hole surgery: a case report.

Authors:  Ji Hwan Lee; Taekjune Lee; Sung Chul Lee; Christopher Seungkyu Lee
Journal:  BMC Ophthalmol       Date:  2015-04-28       Impact factor: 2.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.